Market Trends

Nvidia turns financier, CAVA's traffic sizzles, Berkshire ends its 3-year drought, and more...

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.

SCHD offers lower costs and boasts stronger one-year returns than HDV, which maintains a more concentrated portfolio of high-yielding U.S. stocks.

Here are four low-cost, well-diversified stock ETFs that I would recommend for my own child's 401(k) contributions.

Investing is hard. We should all try to stay humble about it.

Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification.

It all starts with identifying durable companies with a focus on capital returns.

Fed Chair Kevin Warsh and the Federal Open Market Committee (FOMC) have a "core" dilemma.

The Buffett indicator, a metric popularized by the Oracle of Omaha, is at a record high.

The S&P 500 Shiller CAPE ratio measures stock market valuations over a long-term horizon.

Today, Aug. 13, 2026, softer wholesale and consumer inflation figures ease Fed pressure and boost markets.

Small-cap stocks are surging, but how you own them matters more than most investors realize.

State Street's aerospace fund turned $1,000 into $2,346 over five years, while the airline-focused competitor lagged with a steeper drawdown.

Ackman dumped Alphabet and doubled down on three megacap tech winners. Here's what has to go right for the outperformance to continue.

Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.

Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund.

Silver delivered 70.7% returns over one year but swung 52% deeper in drawdowns. Gold's lower costs and stability appeal to risk-averse bullion investors.

The Vanguard Information Technology ETF has more than doubled the gains of the S&P 500 thus far in 2026.

Active management and concentrated bets drove a 42% one-year return, though the lower-cost Invesco alternative offers broader diversification across 60 healthcare stocks.

Both earnings and revenue growth were the highest since 2021.